Related content

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

By Eap Chin   Buclin Thierry   Hustert Elisabeth   Bleiber Gabriela   Golay Kerry   Aubert Anne-Catherine   Baumann Pierre   Telenti Amalio   Kerb Reinhold  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 4, 2004-06 ,pp. : 231-236

Springer Publishing Company

Access to resources Recommend Favorite

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy

By Elens Laure   van Gelder Teun   Hesselink Dennis A   Haufroid Vincent   van Schaik Ron HN  

Pharmacogenomics, Vol. 14, Iss. 1, 2013-01 ,pp. : 47-62

Future Medicine

Access to resources Recommend Favorite

In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6

By Weiss Johanna  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 378, Iss. 3, 2008-09 ,pp. : 275-282

Springer Publishing Company

Access to resources Recommend Favorite

Effect of eurycomanone on cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 in vitro

By Pan Yan   Tiong Kai   Abd-Rashid Badrul   Ismail Zakiah   Ismail Rusli   Mak Joon   Ong Chin  

Journal of Natural Medicines, Vol. 68, Iss. 2, 2014-04 ,pp. : 402-406

Springer Publishing Company

Access to resources Recommend Favorite

Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects

By  

Clinical Pharmacology In Drug Development, Vol. 3, Iss. 2, 2014-03 ,pp. : 151-157

John Wiley & Sons Inc

Access to resources Recommend Favorite